Document Detail

Behavioral animal models of antipsychotic drug actions.
MedLine Citation:
PMID:  23129339     Owner:  NLM     Status:  In-Data-Review    
Basic research in animals represents a fruitful approach to study the neurobiological basis of brain and behavioral disturbances relevant to neuropsychiatric disease and to establish and evaluate novel pharmacological therapies for their treatment. In the context of schizophrenia, there are models employing specific experimental manipulations developed according to specific pathophysiological or etiological hypotheses. The use of selective lesions in adult animals and the acute administration of psychotomimetic agents are indispensable tools in the elucidation of the contribution of specific brain regions or neurotransmitters to the genesis of a specific symptom or collection of symptoms and enjoy some degrees of predictive validity. However, they may be inaccurate, if not inadequate, in capturing the etiological mechanisms or ontology of the disease needed for a complete understanding of the disease and may be limited in the discovery of novel compounds for the treatment of negative and cognitive symptoms of schizophrenia. Under the prevailing consensus of schizophrenia as a disease of neurodevelopmental origin, we have seen the establishment of neurodevelopmental animal models which aim to identify the etiological processes whereby the brain, following specific triggering events, develops into a "schizophrenia-like brain" over time. Many neurodevelopmental models such as the neonatal ventral hippocampus (vHPC) lesion, methylazoxymethanol (MAM), and prenatal immune activation models can mimic a broad spectrum of behavioral, cognitive, and pharmacological abnormalities directly implicated in schizophrenic disease. These models allow pharmacological screens against multiple and coexisting schizophrenia-related dysfunctions while incorporating the disease-relevant concept of abnormal brain development. The multiplicity of existing models is testimonial to the multifactorial nature of schizophrenia, and there are ample opportunities for their integration. Indeed, one ultimate goal must be to incorporate the successes of distinct models into one unitary account of the complex disorder of schizophrenia and to use such unitary approaches in the further development and evaluation of novel antipsychotic treatment strategies.
Daria Peleg-Raibstein; Joram Feldon; Urs Meyer
Related Documents :
23398689 - Field et al. redux.
24479899 - Methods for observed-cluster inference when cluster size is informative: a review and c...
24182239 - Proof of heisenberg's error-disturbance relation.
25025739 - Natural humic substances effects on the life history traits of latonopsis australis sar...
23795209 - The effect direction plot: visual display of non-standardised effects across multiple o...
19683849 - Improved chest recoil using an adhesive glove device for active compression-decompressi...
12858999 - Between economics and ecology: some historical and philosophical considerations for mod...
10940219 - Probing the kinetics of beta-amyloid self-association.
20480699 - Applying information theory to small groups assessment: emotions and well-being at work.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Handbook of experimental pharmacology     Volume:  -     ISSN:  0171-2004     ISO Abbreviation:  Handb Exp Pharmacol     Publication Date:  2012  
Date Detail:
Created Date:  2012-11-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902231     Medline TA:  Handb Exp Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  361-406     Citation Subset:  IM    
Laboratory of Translational Nutrition Biology, Swiss Federal Institute of Technology (ETH) Zürich, Schorenstrasse 16, 8603, Schwerzenbach, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biomarkers for antipsychotic therapies.
Next Document:  Lung function outcome at school age in very low birth weight children.